- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
Novo Nordisk A/S at American Heart Association Conference Transcript
/-&
Good evening, and a warm welcome to Novo Nordisk Investor Event in connection with the American Heart Association Annual Conference here in Philadelphia. My name is Daniel, and I'm heading up Investor Relations at Novo Nordisk. Also a warm welcome to those of you following the webcast online.
I have to say that even though we're going to talk about SELECT and the results have been published today, that we could still end up talking about forward-looking statements. So please look at the disclaimers as always. This is the agenda we are going to discuss SELECT in detail, and we'll have two presenters, and I'll get back to them.
Just before we dive into SELECT, this is our strategic aspirations. This is the way we report on our strategy progress in Novo Nordisk. We recently reported our results for the first 9 months of this year, and we continue to make progress on our different aspirations. Notice we now treat around 40 million people within diabetes. Majority of those being on insulin,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |